Anti-Craving Drug Eases Pain of Fibromyalgia

Naltrexone being studied for immune-related disorders.

A drug frequently used to treat heroin and alcohol addiction also eased the pain of women suffering the symptoms of fibromyalgia, according to a Stanford study published in the April 17 journal of Pain Medicine.

Fibromyalgia remains a controversial diagnosis. As reported by Coco Ballantyine in Scientific American online, it is a “mysterious ailment whose symptoms include chronic widespread muscle pain, fatigue, sleep problems, anxiety and depression, often appears between the ages of 34 and 53 and is more common in women.”

Jarred Younger and Sean Mackey of the Stanford School of Medicine’s pain management division reported that pain and fatigue ratings for the women dropped by 30% over the 14 weeks of the study. “Patients’ reactions were really quite profound,” said Mackey. “Some people went back to work really improving their quality of life.”

Tara Campbell, one of the patients involved in the study, told the Stanford News Service that she was feeling “really, really good.” She said “my improvement was about 40 percent in the study. When you’re not capable of doing much of anything, that’s a lot... I’m much more back to normal.”

Younger said he became interested in studying naltrexone after he began questioning patients who claimed to be suffering from the disorder. “I was asking patients, ‘Does anything work for you?’ A lot of people in support groups were saying, ‘Yeah, I tried naltrexone and it works for me.’”

Naltrexone is currently used as a treatment for heroin addiction and for alcoholism. (See my post, "Drugs for Alcoholism.") Naltrexone works by locking into central nervous system receptors normally occupied by opiates or by the body’s own endorphins. Researchers like Younger, however, believe that naltrexone also dampens the activity of immune cells known as microglia that are involved in inflammatory responses.

It is not uncommon for scientists to investigate the additional effects of drugs in common use. “From a regulatory point of view,” said Canadian addiction researcher Edward Sellers in my book, The Chemical Carousel, “companies don’t try to develop [new drugs] for forty-three different things. But these drugs still carry with them many other pharmacologic actions. The history of virtually every drug that comes to market is that all these other secondary applications start to manifest themselves.”

Graphics Credit: http://www.aocbv.com/fibromyalgia.html

The Chemical Carousel

What Science Tells Us About Beating Addiction, by Dirk Hanson.


My book on addiction research is now available for purchase online at AMAZON, BOOKSURGE, ABEBOOKS, AND ALIBRIS.

FROM THE PUBLISHER:
The Chemical Carousel is an in-depth look at addiction science and medical treatments for drug dependence and alcoholism. An experienced science and business journalist, author Hanson brings a complex and widely misunderstood subject out of the shadows and into the light of understanding. In this groundbreaking and highly readable examination of addiction science and the biological, emotional, and scientific underpinnings of substance abuse, The Chemical Carousel breaks through the myths, while presenting the surprising and cutting-edge facts about addiction and its medical origins. Hanson leaves no stone unturned in this invaluable examination of why people become addicted.
ISBN-13 978-1439212998
$20.95 Trade Paperback
472 pages
Notes, selected bibliography, index

BOOKSURGE PUBLISHING www.booksurge.com

addiction drugsmedical marijuanaalcoholics anonymoussmokingdopaminenicotine

Snorting Drugs Can Expose You To Hepatitis C

Recent clinical evidence for “intranasal transmission.”

Classify this item in the “not good news” file. Hepatitis C—it’s not just for syringe users anymore. Contrary to previous theory, dirty needles or direct blood exposure may not be necessary. While bodily fluids have always been suspect, researchers at the University of Rochester Medical Center and other institutions have discovered evidence of the hepatitis C virus (HCV) in nasal secretions left in straws used to sniff drugs.

It is no secret that the regular practice of snorting or sniffing drugs can lead to inflammation and bleeding in the tender mucous membranes in the nose. This complicates the risk of using “shared drug-sniffing implements,” as the study refers to them.

According to a report of the work in NIDA Addiction Research News, the method of disease transmission is unknown in an estimated 20 percent of Hepatitis C infections. NIDA said the researchers “asked participants to snort air through a straw in a way that would mimic their normal drug-sniffing behavior to determine whether sniffing implements became contaminated. The straws were then tested for blood and HCV.”

In the study of 38 intranasal drug users, all of whom had active Hepatitis C infections, “researchers found trace amounts of blood in 74 percent of mucus samples and on 8 percent of the straws used for sniffing. In addition, they detected HCV in 13 percent of mucus samples and on 5 percent of the straws.” The Hepatitis C virus is capable of surviving on surfaces for as long as 16 hours. The scientists conclude that the results, while preliminary, “lend important virological and clinical support to the intranasal HCV transmission hypothesis.”

In fact, the authors of the study suggest that the findings are quite likely conservative, given that the Hepatitis C virus is more likely to “occur in the nasal secretions with greater frequency during episodes of active drug sniffing, which may exacerbate the discharge of nasal fluids and blood.”

The findings were reported in the October 1, 2008 issue of Clinical Infectious Diseases.

PHOTO CREDIT: Hepatitis C Harm Reduction Project

addiction drugs

The Economics of Legalization

British study sees annual savings of $20 billion.

Legalizing heroin and cocaine would save Great Britain as much as $20 billion a year, a British drug reform group claims in a 50-page report issued this week. The Transform Drug Policy Foundation said the savings would come primarily in the form of reductions in the cost of government enforcement.

The report, “A Comparison of the Cost-effectiveness of Prohibition and Regulation,” purports to be the first cost-benefit analysis ever undertaken with respect to drug prohibition in Britain. According to an analysis in the Drug War Chronicle, “the British government has relied on mere assertion to justify maintaining prohibition and to argue that the harms of legalization would outweigh its benefits.” The drug reform foundation examined criminal justice, drug treatment, crime, and other social costs, and concluded that “a regime of regulated legalization would accrue large savings over the current prohibitionist policy.”

The Drug War Chronicle reported that the reform group “postulated four different legalization scenarios based on drug use levels declining by half, staying the same, increasing by half, and doubling. Even under the worst-case scenario, with drug use doubling under legalization, Britain would still see annual savings of $6.7 billion. Under the best case scenario, the savings would approach $20 billion annually.”

Specifically, the report says that “even in the highly unlikely event of heroin and cocaine use increasing 100%, the net benefit of a move to regulation and control remains substantial. The economic benefits of regulation identified are also of a magnitude to suggest that even with significant margins of error we can assume that legally regulated markets would deliver substantial net savings to the Treasury and wider society.”

In addition, the report notes that “The Government has also repeatedly failed to acknowledge that prohibition is a policy choice, not a fixed feature of the policy landscape that must be worked within, or around.”

“The most striking conclusion from the analysis of current costs,” the report concludes, “is that prohibition of drugs is the root cause of almost all drug-related acquisitive crime, and that this crime constitutes the majority of drug-related harms and costs to society.”

The full report from the Transform Drug Policy Foundation can be downloaded in PDF format here.

Photo Credit: http://thewhitedsepulchre.blogspot.com

addiction drugs

The Perils of Polydrug Abuse

Methadone and benzodiazepines.

For patients in opiate treatment programs, benzodiazepine use represents both a barrier to recovery and a potentially life threatening situation. The combination of benzodiazepines and methadone can lead to fatal overdose.

The five most commonly prescribed benzodiazepines fall into two major categories. High potency medications include Xanax (Alprazolam), with a short half-life of six to 12 hours, and Ativan (Lorazepam), with a slightly longer half-life. The low-potency benzodiazepines are represented by the short-lived Restoril (Temazepam), and the longer-lasting Valium (Diazepam), with a half-life of 20 to 100 hours. The fifth popular benzodiazepine, Klonopin (Clonazepam) is a high-potency drug with a half-life of 18 to 50, the highest in its class. Their primary clinical uses include the treatment of anxiety disorders, insomnia, convulsions, and muscle spasms. They also find use in the treatment of acute mania, catatonia, and detoxification from alcohol.

While some patients are able to use benzodiazepines safely at low dosage for years, patients with a history of opiate addiction are a high-risk category for these medications. Tolerance develops quickly in patients who use benzodiazepines to “boost” the effect of methadone, or as a sedative during opioid withdrawal. Since high doses of benzodiazepines cause respiratory depression, even among opioid users who have developed a high tolerance to such effects, the combination increases the risk of severe intoxication, injuries, or fatal overdose.

In addition, benzodiazepines and methadone interact pharmacologically through the actions of the CYP450 liver enzyme, which detoxifies both substances. If the work load for CYP450 becomes too great, the result can be an accumulation of high levels of methadone in the body.

It has been estimated that “80 percent of benzodiazepine abuse is part of polydrug abuse, most commonly with opioids.” In a two-year study by the National Institute of Drug Abuse (NIDA), 73 per cent of heroin users also used benzodiazepines more often than weekly.

According to a recent Canadian study of 172 subjects, the reported lifetime prevalence of benzodiazepine abuse in methadone maintenance patients ranged from 67 to 94 percent, with two-thirds of the patients reporting benzodiazepine use during the past 6 months. Patients who took benzodiazepines also reported more previous opioid overdoses, according to the study. And women are more likely than men to abuse benzodiazepines. In a study by Australia’s National Drug and Alcohol Research Centre (NDARC), researchers conducting a five-year study of heroin overdoses in New South Wales found that attempted suicide by benzodiazepine overdose was more common than attempted suicide by heroin overdose.

Methadone maintenance patients need to be questioned carefully about benzodiazepine use. By doing so, physicians and other caregivers can work toward actively decreasing the likelihood of treatment failure or fatal methadone overdose.

Photo Credit: www.drug.uz

House Tobacco Bill Moves to Senate

Bill would give FDA control over nicotine products.

It is one of the most popular drugs in America, used and abused by millions. Yet it is not regulated by any government agency. There is no federal testing, no quality control, no standards of any kind. As representative Jared Polis (D-Colorado) memorably told the U.S. House of Representatives: “Tobacco use is the single largest cause of preventable death in our country. Yet it continues to receive less regulation than a head of lettuce.”

That deplorable situation may soon change, as the U.S. Senate takes up a bill recently passed by the House. The legislation would give the Food and Drug Administration (FDA) broad new powers to regulate the tobacco industry for the first time in history.

The house bill is similar to one passed last session, which died in the Senate after it was opposed by the Bush administration. According to reports by Duff Wilson in the New York Times, the legislation would enable the FDA to “approve or reject current and proposed tobacco products and ingredients, based on scientific and health findings.” The FDA would be able to restrict harmful chemicals and reject new tobacco products, but in a major concession to Philip Morris, the nation’s largest cigarette maker, the bill “would not allow a complete ban of tobacco products, or permit the agency to order the complete removal of nicotine.” The Times article also said the bill would lead to larger and more graphic warning labels on cigarette packs.

Senator Edward Kennedy (D-Massachusetts) said he plans to introduce the bill later this month. The legislation is supported by President Obama. An official statement released by the administration said that tobacco use “is a major factor driving the increasing costs of health care in the U.S. and accounts for over a hundred billion dollars annually in financial costs to the economy.” Attempts to mandate FDA regulation of tobacco have been made repeatedly over the past decade.

Tobacco industry supporters have vowed to fight the bill on the Senate floor. Senator Richard Burr (R-North Carolina) said he was considering a filibuster. House Republican Virginia Foxx, also of North Carolina, derided the legislation as “an unnecessary and expensive regulatory scheme at the expense of our rural farming communities.” North Carolina is the country’s leading tobacco growing state.

A spokesperson for the American Heart Association said the Senate was expected to act quickly on the bill: “This has certainly been a passion of Senator Kennedy’s and a legacy he can leave to the public health of America.”

Photo Credit: Winston-Salem Journal

smoking nicotine